This difference by type 2 diabetes status reflects the fact that approved doses differ for chronic weight management versus treatment of type 2 diabetes, where doses for type 2 diabetes can typically start off lower and only increase if deemed necessary
In a large systemic review and network analysis, including several GLP-1RAs, subcutaneous semaglutide was the only glucose-lowering drug for which this signal was observed (120)
Despite their differences in dosage, frequency, and intended use, Ozempic, Wegovy, Mounjaro, and Saxenda all function by influencing hormonal activity in the body, particularly the hormones involved in regulating blood sugar and appetite
Wednesday and Sunday are closed
The key point is that regain is gradual and can be mitigated with strategic interventions